We have built a robust pipeline of TRuC-T cell product candidates for solid and hematologic cancers.
The versatility of our platform is highlighted by the multiple programs and multiple formats of the product candidates in our pipeline. In preclinical studies with TRuC-T cell product candidates, we have shown better anti-tumor activity, longer persistence, and lower cytokine release compared to CAR-T cells bearing the same...
We have built a robust pipeline of TRuC-T cell product candidates for solid and hematologic cancers.
The versatility of our platform is highlighted by the multiple programs and multiple formats of the product candidates in our pipeline. In preclinical studies with TRuC-T cell product candidates, we have shown better anti-tumor activity, longer persistence, and lower cytokine release compared to CAR-T cells bearing the same tumor antigen binding domains. The FDA cleared the IND for TC-210, our lead candidate, in January 2019, and we plan to initiate TC-210’s Phase 1/2 clinical trial in early 2019.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.